Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 03 May 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Antibodies to infliximab and risk of infusion reactions in patients with IBD

The most recent issue of the Inflammatory Bowel Diseases investigates antibodies to infliximab and risk of infusion reactions in patients with IBD.

News image

Antibodies to infliximab have been associated with a risk of infusion reactions in some studies of patients with inflammatory bowel disease.

However, many factors, such as immunomodulators and dosing schedule, may influence this association.

Dr O’Meara and colleagues provided a pooled estimate of the risk of infusion reactions according to patients’ antibodies to infliximab status and analyze the relationship of immunomodulators to this risk.

Public databases were searched for eligible studies.

Quality assessment was undertaken for all studies using Grading of Recommendations Assessment, Development and Evaluation criteria.

Raw data from studies meeting inclusion criteria were pooled for meta-analysis of effect estimates.

7 of the 8 studies had a high risk of bias in at least 1 quality domain
Inflammatory Bowel Diseases

Sensitivity analysis was performed for all outcomes. Funnel plot was performed to assess for publication bias.

The team identified 8 studies met the inclusion criteria, with a pooled total of 1351 subjects.

The researchers found 7 of the 8 studies had a high risk of bias in at least 1 quality domain.

The cumulative data indicated that there was a higher risk ratio (RR) of any acute infusion reaction, and severe infusion reactions in patients with antibodies to infliximab when compared with patients without antibodies to infliximab.

The team noted that RR of delayed hypersensitivity reactions was not significantly different between antibodies to infliximab positive and negative patients.

The researchers reported that patients prescribed immunomodulators during maintenance infliximab therapy had a reduction in their risk for antibodies to infliximab development, and infusion reactions.

Dr O’Meara's team concludes, "The presence of antibodies to infliximab is associated with a significantly higher risk of acute infusion reactions, but not delayed hypersensitivity reactions, in patients with inflammatory bowel disease."

"Concomitant immunomodulators reduce this risk."

Inflamm Bowel Dis 2014: 20(1): 1-6
21 January 2014

Go to top of page Email this page Email this page to a colleague

 03 May 2016 
Surgery vs medical therapy for GERD
 03 May 2016 
Vedolizumab for IBD
 03 May 2016 
PPIs and gut microbiota
 02 May 2016 
Resection of colorectal polyps
 02 May 2016 
Genetic variant that increase NAFLD risk
 02 May 2016 
Mycophenolate mofetil as first-line treatment of autoimmune hepatitis
 29 April 2016 
Crohn's disease associated genes
 29 April 2016 
Simvastatins and survival in cirrhosis
 29 April 2016 
HCV infection in Baby Boomers with Medicare
 28 April 2016 
Racial disparities in survival from colon cancer
 28 April 2016 
Diarrheal diseases in children
 28 April 2016 
Birth outcomes in women with IBD receiving assisted reproduction
 27 April 2016 
Dust mite and human GI tract
 27 April 2016 
Ultra-short celiac disease
 27 April 2016 
Celiac disease in adults
 26 April 2016 
Polyp detection during colonoscopy
 26 April 2016 
Guidelines for nutrition therapy in hospitalized patients
 26 April 2016 
IBS and microscopic colitis
 25 April 2016 
Estrogen deficiency and fibrosis risk in women with NAFLD
 25 April 2016 
Acceptance of Liver transplant center organ offers
 25 April 2016 
Abrupt interruption of beta-blockers in cirrhosis 
 22 April 2016 
Novel method to regenerate the esophagus
 22 April 2016 
Relapse after antiviral treatment in Hep B
 22 April 2016 
Microscopic colitis with NSAIDs and PPIs
 11 April 2016 
Infliximab vs adalimumab in ulcerative colitis
 11 April 2016 
H. pylori in treatment-naïve children
 11 April 2016 
Admissions times and outcomes for ERCP cholangitis
 08 April 2016 
Endoscopic treatment of Crohn's strictures
 08 April 2016 
Nutrition therapy in the hospitalized patient
 08 April 2016 
H.pylori effects on pediatric gastric mucosa
 07 April 2016 
CVD changes after TIPSS
 07 April 2016 
Transanal mesorectal resection for rectal cancer
 07 April 2016 
HBV during immunosuppressive therapies
 06 April 2016 
Adherence to colorectal cancer screening strategies
 06 April 2016 
Duodenal bulb biopsies in childhood celiac disease diagnosis
 06 April 2016 
Lymph node metastasis in early gastric cancer
 05 April 2016 
IBS in the US military
 05 April 2016 
Changes in blood flow in cirrhosis
 05 April 2016 
Colorectal cancer risk with serrated polyps
 04 April 2016 
Noninvasive diagnosis of celiac disease
 04 April 2016 
Metallic vs plastic stents for benign biliary strictures
 04 April 2016 
Adherence to quality indicators improves clinical outcomes in ascites
 01 April 2016 
Colorectal cancer risk with non-malignant colonoscopy findings
 01 April 2016 
Intensive enteral nutrition and severe alcoholic hepatitis
 01 April 2016 
Prognosis after colorectal cancer resection with peritoneal metastasis
 31 March 2016 
Anesthesia services during colonoscopy
 31 March 2016 
Alcohol and glucose tolerance in NAFLD
 31 March 2016 
Management of Barrett’s esophagus
 30 March 2016 
Depression and symptoms in IBS
 30 March 2016 
Electronic learning system for colon capsule endoscopy
 30 March 2016 
Gastric cancer screening
 29 March 2016 
Statins and survival in esophageal cancer
 29 March 2016 
Infant feeding practices and celiac disease
 25 March 2016 
Medical therapy and neoplasia regression in familial adenomatous polyposis
 25 March 2016 
Medical therapy compliance and ulcerative colitis recurrence
 25 March 2016 
Predicting outcomes of drug-induced acute liver failure
 24 March 2016 
Thrombocytopenia and multi-organ system failure in acute liver failure
 24 March 2016 
Patients with ulcerative colitis and their concerns
 24 March 2016 
Prediction of relapses in IBD
 23 March 2016 
Thiopurine therapy in IBD

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us